Table 3.
Two-year overall survival, local progression-free survival, and distant-metastasis free survival rates for patients with lacrimal gland carcinoma, including factors affecting survival
| 2-Y OS (%) | P-value* | 2-Y LPFS (%) | P-value* | 2-Y DMFS (%) | P-value* | |
|---|---|---|---|---|---|---|
| Sex (male vs. female) | 87.5 vs. 67.5 | 0.533 | 87.5 vs. 67.5 | 0.533 | 87.5 vs. 57.1 | 0.353 |
| Age (< 54 vs. ≧ 54) | 85.7 vs. 55.6 | 0.529 | 76.2 vs. 77.8 | 0.621 | 75.0 vs. 66.7 | 0.331 |
| T stage (T1–2 vs. T3–4) | 100.0 vs. 37.5 | 0.013 | 100.0 vs.50.0 | 0.006 | 100.0 vs. 37.5 | 0.002 |
| RT dose (< 66 vs. ≧66 Gy) | 87.5 vs. 50.8 | 0.114 | 63.5 vs. 88.9 | 0.464 | 75.0 vs. 66.7 | 0.344 |
| Cell types (ACC vs. others) | 87.5 vs. 50.0 | 0.517 | 66.7 vs. 87.5 | 0.581 | 77.8 vs. 66.7 | 0.914 |
| Margin (positive vs. negative) | 75.5 vs. 50.0 | 0.43 | 76.9 vs. 75.0 | 0.944 | 69.2 vs. 80.0 | 0.76 |
| PNI (positive vs. negative) | 66.7 vs. 71.4 | 0.438 | 58.3 vs. 90.0 | 0.264 | 58.3 vs. 80.0 | 0.583 |
| LVSI (positive vs. negative) | 80.0 vs. 75.0 | 0.879 | 80.0 vs. 75.0 | 0.879 | 83.3 vs. 66.7 | 0.292 |
*Log-rank test
Y year, OS overall survival, LPFS local progression free survival, DMFS distant-metastasis free survival, RT radiotherapy, ACC adenoid cystic carcinoma, PNI perineural invasion, LVSI lymphovascular invasion